Unlike pharmaceutical GLP1 receptor agonists such as semaglutide, this supplement does not contain prescription drugs , making it more accessible to consumers and easier for supplement distributors to bring to market
doi:10.1016/S0140-6736(18)32260-8 32
How Do Their Mechanisms Differ
[30] Aziz F, Khan MF, Moiz A
Yeo and colleagues explained that with rising obesity in the U.S., the increasing prevalence of GLP-1 receptor agonists prescribed for obesity may contribute to drug shortages. Further, drug shortages may exacerbate the existing nationwide racial and ethnic disparities in GLP-1 receptor agonist prescriptions, they wrote, adding that the results suggest a call for strategies to address the growing demand and ensure equitable access to the drugs.
Available from: Brown J, Clarke C, Johnson Stoklossa C, Sievenpiper J